The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

Cara E. Toscan, Hannah McCalmont, Amir Ashoorzadeh, Xiaojing Lin, Zhe Fu, Louise Doculara, Hansen J. Kosasih, Roxanne Cadiz, Anthony Zhou, Sarah Williams, Kathryn L. Evans, Faezeh Khalili, Ruilin Cai, Kristy L. Yeats, Andrew J. Gifford, Russell Pickford, Chelsea Mayoh, Jinhan Xie, Michelle J. Henderson, Toby N. Trahair, Adam V. Patterson, Jeff B. Smaill, Charles E. de Bock, Richard B. LockBlood 2024 · DOI

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed a novel prodrug, ACHM-025, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. We show that ACHM-025 has potent in vivo efficacy against T-ALL patient-derived xenografts (PDXs) and eradicated the disease in 7 PDXs. ACHM-025 was significantly more effective than cyclophosphamide both as a single agent and when used in combination with cytarabine/6-mercaptopurine. Notably, ACHM-025 in combination with nelarabine was curative when used to treat a chemoresistant T-ALL PDX in vivo. The in vivo efficacy of ACHM-025 directly correlated with AKR1C3 expression levels, providing a predictive biomarker for response. Together, our work provides strong preclinical evidence highlighting the potential of ACHM-025 as a targeted and effective therapy for aggressive forms of T-ALL.
BibTeX
@inproceedings{toscan2024third,
  author = {Cara E. Toscan and Hannah McCalmont and Amir Ashoorzadeh and Xiaojing Lin and Zhe Fu and Louise Doculara and Hansen J. Kosasih and Roxanne Cadiz and Anthony Zhou and Sarah Williams and Kathryn L. Evans and Faezeh Khalili and Ruilin Cai and Kristy L. Yeats and Andrew J. Gifford and Russell Pickford and Chelsea Mayoh and Jinhan Xie and Michelle J. Henderson and Toby N. Trahair and Adam V. Patterson and Jeff B. Smaill and Charles E. de Bock and Richard B. Lock},
  title = {{The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia}},
  booktitle = {Blood},
  year = {2024},
  doi = {10.1038/s41408-024-01180-x},
}

Loading related content...

Figure